Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.

[1]  A. Yoshizawa,et al.  Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. , 2013, Human pathology.

[2]  C. Sima,et al.  Thyroid transcription factor‐1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma , 2013, Cancer.

[3]  Y. Yatabe,et al.  HNF4&agr; as a Marker for Invasive Mucinous Adenocarcinoma of the Lung , 2013, The American journal of surgical pathology.

[4]  D. Park,et al.  Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin , 2012, Modern Pathology.

[5]  M. Sonobe,et al.  Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas , 2012, Annals of Surgical Oncology.

[6]  I. Takeyoshi,et al.  Clinicopathological features of lung adenocarcinoma with KRAS mutations , 2011, Cancer.

[7]  T. Kodama,et al.  The predominant expression of hepatocyte nuclear factor 4α (HNF4α) in thyroid transcription factor‐1 (TTF‐1)‐negative pulmonary adenocarcinoma , 2011, Histopathology.

[8]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  R. Tavares,et al.  Comparison of Thyroid Transcription Factor-1 Expression by 2 Monoclonal Antibodies in Pulmonary and Nonpulmonary Primary Tumors , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  Y. Yatabe.  EGFR mutations and the terminal respiratory unit , 2010, Cancer and Metastasis Reviews.

[11]  A. Yoshizawa,et al.  Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[12]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[13]  S. Hirohashi,et al.  Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma , 2007, Cancer science.

[14]  Y. Yatabe,et al.  Epidermal growth factor receptor mutations in lung cancers , 2007, Pathology international.

[15]  Takayuki Kosaka,et al.  Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Aburatani,et al.  Dysregulated expression of P1 and P2 promoter‐driven hepatocyte nuclear factor‐4α in the pathogenesis of human cancer , 2006, The Journal of pathology.

[17]  K. Sueishi,et al.  Interleukin-10 expression is positively correlated with oxidized LDL deposition and inversely with T-lymphocyte infiltration in atherosclerotic intimas of human coronary arteries. , 2006, Pathology, research and practice.

[18]  F. Bray,et al.  International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.

[19]  M. Sonobe,et al.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2005, British Journal of Cancer.

[20]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[21]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[22]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[23]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[24]  S. Lau,et al.  Expression of Thyroid Transcription Factor-1, Cytokeratin 7, and Cytokeratin 20 in Bronchioloalveolar Carcinomas: an Immunohistochemical Evaluation of 67 Cases , 2002, Modern Pathology.

[25]  K. Anagnostopoulou,et al.  A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. , 2001, Molecular and cellular probes.

[26]  N. Goldstein,et al.  Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. , 2001, American journal of clinical pathology.

[27]  N. Letwin,et al.  Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. , 2000, American journal of respiratory cell and molecular biology.

[28]  J. Davies,et al.  MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions , 1996, Glycoconjugate Journal.

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  J. Voynow,et al.  Respiratory tract mucin genes and mucin glycoproteins in health and disease. , 2006, Physiological reviews.

[31]  S. Gould,et al.  Developmental expression of mucin genes in the human respiratory tract. , 1997, American journal of respiratory cell and molecular biology.

[32]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.